Pharmacist Intervention to Improve Smoking Cessation
Launched by UNIVERSITY OF IOWA · Apr 16, 2025
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help smokers quit using support from pharmacists. Specifically, the trial will look at whether talking to a pharmacist over the phone can encourage smokers to stop smoking, especially for those who are already being screened for lung cancer. The researchers want to find out if smokers are willing to participate in this program and if those who receive the pharmacist's help are more likely to quit compared to those who do not.
To be eligible for the trial, participants need to be current smokers who are part of the Lung Cancer Screening Program. Participants in the study will complete a survey at the beginning and end of the trial. Those in the intervention group will also have phone calls with a pharmacist at various points over three months to discuss their smoking habits and receive support. This trial is not yet recruiting participants, but it aims to provide valuable insights into effective ways to help people quit smoking.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Current smoker
- • Current patient in the Lung Cancer Screening Program
- Exclusion Criteria:
- • Unable to speak/read English
- • Unable to provide their own written informed consent
About University Of Iowa
The University of Iowa, a leading academic and research institution, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses the expertise of its faculty and researchers to investigate cutting-edge therapies and treatments across various medical fields. Committed to ethical research practices and patient-centered care, the University of Iowa strives to contribute significantly to medical knowledge and improve health outcomes through rigorous scientific inquiry and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jacob E Simmering, PhD
Principal Investigator
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported